Bone Fracture – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Bone Fracture – Pipeline Review, H1 2017’, provides an overview of the Bone Fracture pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Fracture, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Bone Fracture

– The report reviews pipeline therapeutics for Bone Fracture by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bone Fracture therapeutics and enlists all their major and minor projects

– The report assesses Bone Fracture therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bone Fracture

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bone Fracture

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

American Gene Technologies International Inc

Arcarios BV

AstraZeneca Plc

Biogenomics Ltd

BiologicsMD Inc

Biopharm GmbH

Bone Therapeutics SA

Cellmid Ltd

Chrysalis BioTherapeutics Inc

Entera Bio Ltd

Escape Therapeutics Inc

ethris GmbH

Kuros Biosciences AG

Novartis AG

Pluristem Therapeutics Inc

TissueGene Inc

Viking Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bone Fracture Overview

Bone Fracture Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bone Fracture Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bone Fracture Companies Involved in Therapeutics Development

American Gene Technologies International Inc

Arcarios BV

AstraZeneca Plc

Biogenomics Ltd

BiologicsMD Inc

Biopharm GmbH

Bone Therapeutics SA

Cellmid Ltd

Chrysalis BioTherapeutics Inc

Entera Bio Ltd

Escape Therapeutics Inc

ethris GmbH

Kuros Biosciences AG

Novartis AG

Pluristem Therapeutics Inc

TissueGene Inc

Viking Therapeutics Inc

Bone Fracture Drug Profiles

ALLOB Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-2858 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimagrumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMD-1221 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyndacel-M Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dibotermin alfa biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate BMP2 and VEGF for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAL-436/9 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KUR-111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KUR-113 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LWnt-3a Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Midkine for Bone Fractures Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Activate BMP-2 for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OsteoStem Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-PAD Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Agonize PTH1R for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rusalatide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Metabolic and Musculoskeletal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Musculoskeletal and Metabolic Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPI-86 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Fracture Repair Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Osteoporosis and Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-B Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-5211 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bone Fracture Dormant Projects

Bone Fracture Discontinued Products

Bone Fracture Product Development Milestones

Featured News & Press Releases

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016

Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody

Jun 24, 2016: Cellmid: New Publication And Patent Application For Midkine Antibody

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study

Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference

Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial

Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture

Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects

Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting

Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture

Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture

Mar 23, 2015: Bone Therapeutics treats first patients in ALLOB Phase IIA spinal fusion trial

Jan 19, 2015: Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB Phase I/IIA Delayed-Union Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bone Fracture, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bone Fracture Pipeline by American Gene Technologies International Inc, H1 2017

Bone Fracture Pipeline by Arcarios BV, H1 2017

Bone Fracture Pipeline by AstraZeneca Plc, H1 2017

Bone Fracture Pipeline by Biogenomics Ltd, H1 2017

Bone Fracture Pipeline by BiologicsMD Inc, H1 2017

Bone Fracture Pipeline by Biopharm GmbH, H1 2017

Bone Fracture Pipeline by Bone Therapeutics SA, H1 2017

Bone Fracture Pipeline by Cellmid Ltd, H1 2017

Bone Fracture Pipeline by Chrysalis BioTherapeutics Inc, H1 2017

Bone Fracture Pipeline by Entera Bio Ltd, H1 2017

Bone Fracture Pipeline by Escape Therapeutics Inc, H1 2017

Bone Fracture Pipeline by ethris GmbH, H1 2017

Bone Fracture Pipeline by Kuros Biosciences AG, H1 2017

Bone Fracture Pipeline by Novartis AG, H1 2017

Bone Fracture Pipeline by Pluristem Therapeutics Inc, H1 2017

Bone Fracture Pipeline by TissueGene Inc, H1 2017

Bone Fracture Pipeline by Viking Therapeutics Inc, H1 2017

Bone Fracture Dormant Projects, H1 2017

Bone Fracture Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Bone Fracture, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports